Skip to main content
Top
Published in: BMC Medicine 1/2022

Open Access 01-12-2022 | Affective Disorder | Research article

The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function

Authors: Michael K. Sullivan, Juan-Jesus Carrero, Bhautesh Dinesh Jani, Craig Anderson, Alex McConnachie, Peter Hanlon, Dorothea Nitsch, David A. McAllister, Frances S. Mair, Patrick B. Mark, Alessandro Gasparini

Published in: BMC Medicine | Issue 1/2022

Login to get access

Abstract

Background

Multimorbidity (the presence of two or more chronic conditions) is common amongst people with chronic kidney disease, but it is unclear which conditions cluster together and if this changes as kidney function declines. We explored which clusters of conditions are associated with different estimated glomerular filtration rates (eGFRs) and studied associations between these clusters and adverse outcomes.

Methods

Two population-based cohort studies were used: the Stockholm Creatinine Measurements project (SCREAM, Sweden, 2006–2018) and the Secure Anonymised Information Linkage Databank (SAIL, Wales, 2006–2021). We studied participants in SCREAM (404,681 adults) and SAIL (533,362) whose eGFR declined lower than thresholds (90, 75, 60, 45, 30 and 15 mL/min/1.73m2). Clusters based on 27 chronic conditions were identified. We described the most common chronic condition(s) in each cluster and studied their association with adverse outcomes using Cox proportional hazards models (all-cause mortality (ACM) and major adverse cardiovascular events (MACE)).

Results

Chronic conditions became more common and clustered differently across lower eGFR categories. At eGFR 90, 75, and 60 mL/min/1.73m2, most participants were in large clusters with no prominent conditions. At eGFR 15 and 30 mL/min/1.73m2, clusters involving cardiovascular conditions were larger and were at the highest risk of adverse outcomes. At eGFR 30 mL/min/1.73m2, in the heart failure, peripheral vascular disease and diabetes cluster in SCREAM, ACM hazard ratio (HR) is 2.66 (95% confidence interval (CI) 2.31–3.07) and MACE HR is 4.18 (CI 3.65–4.78); in the heart failure and atrial fibrillation cluster in SAIL, ACM HR is 2.23 (CI 2.04 to 2.44) and MACE HR is 3.43 (CI 3.22–3.64). Chronic pain and depression were common and associated with adverse outcomes when combined with physical conditions. At eGFR 30 mL/min/1.73m2, in the chronic pain, heart failure and myocardial infarction cluster in SCREAM, ACM HR is 2.00 (CI 1.62–2.46) and MACE HR is 4.09 (CI 3.39–4.93); in the depression, chronic pain and stroke cluster in SAIL, ACM HR is 1.38 (CI 1.18–1.61) and MACE HR is 1.58 (CI 1.42–1.76).

Conclusions

Patterns of multimorbidity and corresponding risk of adverse outcomes varied with declining eGFR. While diabetes and cardiovascular disease are known high-risk conditions, chronic pain and depression emerged as important conditions and associated with adverse outcomes when combined with physical conditions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet. 2012;380:37–43.CrossRef Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet. 2012;380:37–43.CrossRef
2.
go back to reference Mair FS, May CR. Thinking about the burden of treatment. BMJ : British Medical Journal. 2014;349: g6680.CrossRefPubMed Mair FS, May CR. Thinking about the burden of treatment. BMJ : British Medical Journal. 2014;349: g6680.CrossRefPubMed
6.
go back to reference Stevens PE, Levin A, Members* for the KDIGOCKDGDWG. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline Ann Intern Med 2013 158 825 30 Stevens PE, Levin A, Members* for the KDIGOCKDGDWG. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline Ann Intern Med 2013 158 825 30
7.
go back to reference Tonelli M, Wiebe N, Manns BJ, et al. Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open. 2018;1:e184852–e184852.CrossRefPubMedPubMedCentral Tonelli M, Wiebe N, Manns BJ, et al. Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open. 2018;1:e184852–e184852.CrossRefPubMedPubMedCentral
8.
go back to reference Sullivan MK, Jani BD, McConnachie A, et al. Hospitalisation events in people with chronic kidney disease as a component of multimorbidity: parallel cohort studies in research and routine care settings. BMC Med. 2021;19:278.CrossRefPubMedPubMedCentral Sullivan MK, Jani BD, McConnachie A, et al. Hospitalisation events in people with chronic kidney disease as a component of multimorbidity: parallel cohort studies in research and routine care settings. BMC Med. 2021;19:278.CrossRefPubMedPubMedCentral
9.
go back to reference van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. a collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.CrossRefPubMed van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. a collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.CrossRefPubMed
11.
go back to reference Bretos-Azcona PE, Sánchez-Iriso E, Cabasés Hita JM. Tailoring integrated care services for high-risk patients with multiple chronic conditions: a risk stratification approach using cluster analysis. BMC Health Serv Res. 2020;20:806.CrossRefPubMedPubMedCentral Bretos-Azcona PE, Sánchez-Iriso E, Cabasés Hita JM. Tailoring integrated care services for high-risk patients with multiple chronic conditions: a risk stratification approach using cluster analysis. BMC Health Serv Res. 2020;20:806.CrossRefPubMedPubMedCentral
13.
14.
go back to reference Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–72.CrossRefPubMed Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–72.CrossRefPubMed
16.
go back to reference Tonelli M, Wiebe N, Fortin M, et al. Correction to: Methods for identifying 30 chronic conditions: application to administrative data. BMC Med Inform Decis Mak. 2019;19:177.CrossRefPubMedPubMedCentral Tonelli M, Wiebe N, Fortin M, et al. Correction to: Methods for identifying 30 chronic conditions: application to administrative data. BMC Med Inform Decis Mak. 2019;19:177.CrossRefPubMedPubMedCentral
17.
go back to reference Huang Z. A fast clustering algorithm to cluster very large categorical data sets in data mining. In: Lu H, Motoda H, Luu H, editors. KDD: techniques and applications. Singapore: World Scientific; 1997. p. 21–34. Huang Z. A fast clustering algorithm to cluster very large categorical data sets in data mining. In: Lu H, Motoda H, Luu H, editors. KDD: techniques and applications. Singapore: World Scientific; 1997. p. 21–34.
18.
go back to reference Kaufman L, Rousseeuw P. Finding groups in data: an introduction to cluster analysis. New York: Wiley; 1990.CrossRef Kaufman L, Rousseeuw P. Finding groups in data: an introduction to cluster analysis. New York: Wiley; 1990.CrossRef
19.
go back to reference Guisado-Clavero M, Roso-Llorach A, López-Jimenez T, et al. Multimorbidity patterns in the elderly: a prospective cohort study with cluster analysis. BMC Geriatr. 2018;18:16.CrossRefPubMedPubMedCentral Guisado-Clavero M, Roso-Llorach A, López-Jimenez T, et al. Multimorbidity patterns in the elderly: a prospective cohort study with cluster analysis. BMC Geriatr. 2018;18:16.CrossRefPubMedPubMedCentral
20.
go back to reference Sjölander A. Regression standardization with the R package stdReg. Eur J Epidemiol. 2016;31:563–74.CrossRefPubMed Sjölander A. Regression standardization with the R package stdReg. Eur J Epidemiol. 2016;31:563–74.CrossRefPubMed
21.
go back to reference R Core Team. R : a language and environment for statistical computing. 2021. R Core Team. R : a language and environment for statistical computing. 2021.
22.
go back to reference Zheng Z, Waikar SS, Schmidt IM, et al. Subtyping CKD patients by consensus clustering: the Chronic Renal Insufficiency Cohort (CRIC) study. Journal of the American Society of Nephrology. 2021;32:639.CrossRefPubMedPubMedCentral Zheng Z, Waikar SS, Schmidt IM, et al. Subtyping CKD patients by consensus clustering: the Chronic Renal Insufficiency Cohort (CRIC) study. Journal of the American Society of Nephrology. 2021;32:639.CrossRefPubMedPubMedCentral
23.
go back to reference Vetrano DL, Roso-Llorach A, Fernández S, et al. Twelve-year clinical trajectories of multimorbidity in a population of older adults. Nat Commun. 2020;11:3223.CrossRefPubMedPubMedCentral Vetrano DL, Roso-Llorach A, Fernández S, et al. Twelve-year clinical trajectories of multimorbidity in a population of older adults. Nat Commun. 2020;11:3223.CrossRefPubMedPubMedCentral
24.
go back to reference Lawson CA, Seidu S, Zaccardi F, et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine. 2021;32: 100739.CrossRefPubMedPubMedCentral Lawson CA, Seidu S, Zaccardi F, et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine. 2021;32: 100739.CrossRefPubMedPubMedCentral
26.
go back to reference Zimbudzi E, Lo C, Robinson T, et al. The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: a qualitative study. PLoS One. 2019;14(7):e0219685. CrossRefPubMedPubMedCentral Zimbudzi E, Lo C, Robinson T, et al. The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: a qualitative study. PLoS One. 2019;14(7):e0219685. CrossRefPubMedPubMedCentral
27.
go back to reference Zimbudzi E, Lo C, Ranasinha S, et al. Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: a longitudinal study. BMJ Open Diabetes Res Care. 2020;8:842.CrossRef Zimbudzi E, Lo C, Ranasinha S, et al. Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: a longitudinal study. BMJ Open Diabetes Res Care. 2020;8:842.CrossRef
28.
go back to reference Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet. 2011;377:2181–92.CrossRef Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet. 2011;377:2181–92.CrossRef
29.
go back to reference Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine. 2001;345:851–60.CrossRefPubMed Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine. 2001;345:851–60.CrossRefPubMed
30.
go back to reference Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New England Journal of Medicine. 1993;329:1456–62.CrossRefPubMed Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New England Journal of Medicine. 1993;329:1456–62.CrossRefPubMed
31.
go back to reference Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. The Lancet. 2005;365:939–46.CrossRef Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. The Lancet. 2005;365:939–46.CrossRef
32.
go back to reference Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. New England Journal of Medicine. 2006;354:131–40.CrossRefPubMed Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. New England Journal of Medicine. 2006;354:131–40.CrossRefPubMed
33.
go back to reference Heerspink HJL, Stefánsson B v, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.CrossRefPubMed Heerspink HJL, Stefánsson B v, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.CrossRefPubMed
34.
go back to reference Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine. 2019;380:2295–306.CrossRefPubMed Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine. 2019;380:2295–306.CrossRefPubMed
35.
go back to reference Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.CrossRefPubMed Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.CrossRefPubMed
36.
go back to reference Lambourg E, Colvin L, Guthrie G, et al. The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis. Kidney Int. 2021;100:636–49.CrossRefPubMed Lambourg E, Colvin L, Guthrie G, et al. The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis. Kidney Int. 2021;100:636–49.CrossRefPubMed
37.
go back to reference Zhu Y, Edwards D, Mant J, Payne RA, Kiddle S. Characteristics, service use and mortality of clusters of multimorbid patients in England: a population-based study. BMC Med. 2020;18:78.CrossRefPubMedPubMedCentral Zhu Y, Edwards D, Mant J, Payne RA, Kiddle S. Characteristics, service use and mortality of clusters of multimorbid patients in England: a population-based study. BMC Med. 2020;18:78.CrossRefPubMedPubMedCentral
38.
go back to reference Zhan M, Doerfler RM, Xie D, et al. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. American Journal of Kidney Diseases. 2020;76:184–93.CrossRefPubMedPubMedCentral Zhan M, Doerfler RM, Xie D, et al. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. American Journal of Kidney Diseases. 2020;76:184–93.CrossRefPubMedPubMedCentral
39.
go back to reference Corsonello A, Fabbietti P, Formiga F, et al. Chronic kidney disease in the context of multimorbidity patterns: the role of physical performance. BMC Geriatr. 2020;20:350.CrossRefPubMedPubMedCentral Corsonello A, Fabbietti P, Formiga F, et al. Chronic kidney disease in the context of multimorbidity patterns: the role of physical performance. BMC Geriatr. 2020;20:350.CrossRefPubMedPubMedCentral
40.
go back to reference Hirst JA, Ordóñez Mena JM, O’Callaghan CA, et al. Prevalence and factors associated with multimorbidity among primary care patients with decreased renal function. PLoS One. 2021;16:e0245131.CrossRefPubMedPubMedCentral Hirst JA, Ordóñez Mena JM, O’Callaghan CA, et al. Prevalence and factors associated with multimorbidity among primary care patients with decreased renal function. PLoS One. 2021;16:e0245131.CrossRefPubMedPubMedCentral
41.
go back to reference Mercer SW, Gunn J, Bower P, Wyke S, Guthrie B. Managing patients with mental and physical multimorbidity. BMJ : British Medical Journal. 2012;345: e5559.CrossRefPubMed Mercer SW, Gunn J, Bower P, Wyke S, Guthrie B. Managing patients with mental and physical multimorbidity. BMJ : British Medical Journal. 2012;345: e5559.CrossRefPubMed
42.
go back to reference Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo AC. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep. 2016;2:94–107.CrossRefPubMedPubMedCentral Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo AC. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep. 2016;2:94–107.CrossRefPubMedPubMedCentral
44.
go back to reference Stokes J, Guthrie B, Mercer SW, Rice N, Sutton M. Multimorbidity combinations, costs of hospital care and potentially preventable emergency admissions in England: a cohort study. PLoS Med. 2021;18:e1003514.CrossRefPubMedPubMedCentral Stokes J, Guthrie B, Mercer SW, Rice N, Sutton M. Multimorbidity combinations, costs of hospital care and potentially preventable emergency admissions in England: a cohort study. PLoS Med. 2021;18:e1003514.CrossRefPubMedPubMedCentral
46.
go back to reference Stevens RJ, Evans J, Oke J, et al. Kidney age, not kidney disease. Can Med Assoc J. 2018;190:E389.CrossRef Stevens RJ, Evans J, Oke J, et al. Kidney age, not kidney disease. Can Med Assoc J. 2018;190:E389.CrossRef
47.
go back to reference Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of multimorbidity in middle-aged and older adults: an analysis of the UK biobank data. Mayo Clin Proc. 2018;93:857–66.CrossRefPubMed Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of multimorbidity in middle-aged and older adults: an analysis of the UK biobank data. Mayo Clin Proc. 2018;93:857–66.CrossRefPubMed
Metadata
Title
The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function
Authors
Michael K. Sullivan
Juan-Jesus Carrero
Bhautesh Dinesh Jani
Craig Anderson
Alex McConnachie
Peter Hanlon
Dorothea Nitsch
David A. McAllister
Frances S. Mair
Patrick B. Mark
Alessandro Gasparini
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-022-02628-2

Other articles of this Issue 1/2022

BMC Medicine 1/2022 Go to the issue